GlaxoSmithKline reports return to profit in second quarter

British drugmaker GlaxoSmithKline posted net profit of more than £1.1 billion in the second quarter on Tuesday following a loss during the equivalent three-month period in 2010.

GSK said in a statement that earnings after tax stood at £1.106 billion (1.252 billion euros, $1.814 billion) in the quarter ending June 30 compared with a net loss of £304 million in the second quarter last year.

The company had fallen into a loss a year ago owing to exceptional legal charges linked to its former diabetes drug Avandia, which has been pulled from European shelves on fears that it increased the risk of heart attack and strokes.

"We have had a strong second quarter," GSK chief executive Andrew Witty said in the company's earnings statement.

"Going forward, we continue to apply sustained pressure to GSK's cost base to realise further savings, through improvements in areas such as support functions, supply chain and procurement efficiency."

GSK was rocked last September when the EU medicines regulator decided to pull Avandia off the shelves. Regulators also restricted its availability in the United States.

The EU decided to pull Avandia owing to concerns over its active substance rosiglitazone. It decided also to halt the sale of Glaxo's other diabetes drugs, Avandamet and Avaglim, since they too contained rosiglitazone.

Meanwhile sales of GSK's herpes treatment Valtrex have been hit by generic competition.

GSK added Tuesday that revenues declined by four percent to £6.72 billion in the second quarter.

add to favorites email to friend print save as pdf

Related Stories

GSK to take $3.4 bln Avandia legal charge

Jan 17, 2011

British drugs firm GlaxoSmithKline said Monday it expects to take a legal charge of £2.2 billion linked to its former blockbuster diabetes product Avandia, sparking a sharp drop in its shares.

Glaxo defends handling of Avandia heart risks

Feb 24, 2010

(AP) -- GlaxoSmithKline said Wednesday a Senate report criticizing its handling of heart risks with its diabetes drug Avandia "mischaracterizes and distorts" the company's record.

Taiwan's AU Optronics sees profit up 54.6 percent

Jul 28, 2010

Taiwan's AU Optronics Corp said Wednesday its net profit in the three months to June jumped 54.6 percent over the previous quarter, partly due to strong demand for high-priced items.

US restricts, EU bans controversial diabetes pill (Update)

Sep 23, 2010

(AP) -- European regulators ordered the diabetes drug Avandia off the market and the Food and Drug Administration placed stringent restrictions on its use in the United States, saying heart attack risks associated with the ...

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

12 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.